Lantheus

Products

Category

Product

Brand

Description

Radiopharmaceuticals: Technologies and Global Markets (PHM171C)

Pylarify (piflufolastat F 18)		A PET radiotracer was indicated for imaging of PSMA-positive lesions in men with prostate cancer. Pylarify was approved by the FDA in May 2021 and commercially launched in the U.S. in June 2021. Curium licensed the European rights of Piflufolastat F 18 from Progenics, a Lantheus company, in 2018. In Europe, Curium markets Piflufolastat F 18 under the brand name Pylclari.
TechneLite (Tc 99m Generator)		The TechneLite generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. It provides the essential nuclear material used by radiopharmacies to radiolabel Tc-99m-based radio tracers.
Xenon-133 Gas		An inhaled radiopharmaceutical imaging agent is primarily used to image the lungs and evaluate pulmonary function. It may also be used to assess cerebral blood flow. Xenon is a by-product of the Mo-99 production process.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment